Targeting Oral Administration of Poorly Soluble Drugs

Due to its strong biocompatibility in the human body, hydroxyapatite has been studied widely in drug delivery applications, chiefly to improve dose efficiency by lesion targeting and slow release of the drug, once it reaches the target site. Sangi’s drug delivery research, in contrast, is aimed at improving the solubility and internal absorption of drugs that are poorly soluble and/or poorly absorbed, allowing them to be administered orally (for example in tablets) instead of by injection or intravenous infusion, for which hospitalization or a hospital visit is usually required. This is especially important in the case of cancer drugs to improve patient quality of life.

Cross-section a image showing a hydroxyapatite-coated drug

To achieve this, Sangi has developed a proprietary technology for coating drugs with hydroxyapatite that can not only improve solubility and absorption of the drug, but also reduce both the volume required and the level of side effects. Sangi’s formulation technology principally targets drugs in Class II of the U.S. Biopharmaceuticals Classification System (BCS) which show high levels of membrane permeability but low solubility, and those in Class IV which show both low membrane permeability and low solubility.

Example showing bezafibrate (BCS Class II), a poorly soluble drug.

Example showing bezafibrate (BCS Class II), a poorly soluble drug. The drug alone fails to dissolve in water (A), but when coated with hydroxyapatite it immediately dissolves (B).